A single-center controlled pilot study to investigate pre- and perioperative therapy with Sorafenib (Nexavar) in patients who are candidates for a curative surgery of renal cell cancer (PREST = preoperative Sorafenib Therapy in RCC).

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 12 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary)
Indications Renal cancer; Renal cell carcinoma
Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
Acronyms PREST

Most Recent Events

30 Jan 2012 Status changed from recruiting to discontinued as reported by EudraCT.
03 Aug 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight